Evaluate Vantage Podcast: Glimmers of Hope or Fool's Gold?

The Evaluate Vantage team have been back to the podcast studio. In this edition, our medtech reporter Elizabeth Cairns and I look at the business side of biopharma now that the first half of 2022 is well behind us, and Q4 is on the horizon. For many in the sector the first half of the year was a period to forget. But the last couple of months have seen some glimmers of hope. We talk about whether they are real – or fool's gold.

For more detail on some of the topics we covered, there are links below to point you in the right direction. 

Want to find out more? Here are some related pieces

• Biopharma, biotech and medtech in Q2: The only way is up (or is it?) 
• Olympus continues medtech’s divestmania
• To back, or back away from, digital health?
• Amgen picks its moment to strike for Chemocentryx